The Medicines Company Newswire

The Medicines Company Newswire

Comprehensive Real-Time News Feed for The Medicines Company.

Results 1 - 20 of 254 in The Medicines Company

  1. Short Interest in The Medicines Company (MDCO) Declines By 8.3%Read the original story w/Photo

    34 min ago | AmericanBankingNews.com

    The Medicines Company was the target of a large decline in short interest in June. As of June 15th, there was short interest totalling 12,560,038 shares, a decline of 8.3% from the May 31st total of 13,696,561 shares.

    Comment?

  2. Medicines Co's antibiotic succeeds in late-stage trialRead the original story w/Photo

    14 hrs ago | Reuters

    The Medicines Co said its experimental antibiotic met the main goals of a late-stage trial on patients with complicated urinary tract infections. The drug, Carbavance , also demonstrated statistical superiority over piperacillin-tazobactam, a combination of existing antibiotic treatments, the company said in a statement.

    Comment?

  3. The Medicines Company (MDCO) Stock Rating Reaffirmed by Leerink SwannRead the original story w/Photo

    19 hrs ago | Daily Political

    ... added to or reduced their stakes in the stock. Bridger Management LLC purchased a new stake in The Medicines Company during the first quarter valued at approximately $98,528,000. Alliancebernstein L.P. boosted its stake in The Medicines Company by ...

    Comment?

  4. The Medicines Company (MDCO) Earns "Buy" Rating from Leerink SwannRead the original story w/Photo

    Thursday Jun 23 | AmericanBankingNews.com

    Shares of The Medicines Company traded up 3.94% during trading on Thursday, hitting $34.54. 1,171,025 shares of the company were exchanged.

    Comment?

  5. The Medicines Company (MDCO) Given Buy Rating at Leerink SwannRead the original story w/Photo

    Thursday Jun 23 | AmericanBankingNews.com

    's stock had its "buy" rating reissued by equities research analysts at Leerink Swann in a report released on Thursday. In other The Medicines Company news, EVP Christopher T. Cox purchased 53,340 shares of the stock in a transaction dated Tuesday, June 7th.

    Comment?

  6. The Medicines Company Completes Divestiture Of Its Non-Core Cardiovascular Assets ToRead the original story

    Tuesday Jun 21 | BioSpace

    The Medicines Company today announced the completion of the previously-disclosed divestiture of its non-core cardiovascular assets, CleviprexA injectable emulsion, KengrealA and rights to Argatroban for Injection to Chiesi USA, Inc. and its parent company Chiesi Farmaceutici S.p.A. The company has received a payment of approximately $264 million in cash and has the potential to receive up to $480 million in sales-based milestone payments. In addition, Chiesi has assumed up to $50 million in milestone payment obligations.

    Comment?

  7. Chiesi Completes the Acquisition of Three Hospital Products --...Read the original story w/Photo

    Wednesday Jun 22 | Market Wire

    Chiesi USA, Inc. and Chiesi Farmaceutici S.p.A., Chiesi USA's parent company, announced today that the companies have finalized the acquisition of multinational rights to KengrealA for injection and CleviprexA injectable emulsion, as well as rights to Argatrobana for Injection, 50 mg per 50 mL from The Medicines Company. All three products are for use in the hospital setting and approved for sale in the U.S. The Medicines Company is receiving approximately $262 million in cash at closing, and is entitled to receive up to $480 million in sales-based milestone and royalty payment obligations.

    Comment?

  8. The Medicines Company Completes Divestiture of its Non-Core Cardiovascular Assets to ChiesiRead the original story w/Photo

    Tuesday Jun 21 | Freshnews

    The Medicines Company today announced the completion of the previously-disclosed divestiture of its non-core cardiovascular assets, CleviprexA injectable emulsion, KengrealA and rights to Argatroban for Injection to Chiesi USA, Inc. and its parent company Chiesi Farmaceutici S.p.A. The company has received a payment of approximately $264 million in cash and has the potential to receive up to $480 million in sales-based milestone payments. In addition, Chiesi has assumed up to $50 million in milestone payment obligations.

    Comment?

  9. The Medicines Company (MDCO) Receives "Buy" Rating from Jefferies GroupRead the original story w/Photo

    Wednesday Jun 15 | Daily Political

    ... made changes to their positions in the company. BlackRock Inc. increased its position in shares of The Medicines Company by 28.3% in the first quarter. BlackRock Inc. now owns 4,554 shares of the company's stock worth $145,000 after buying an ...

    Comment?

  10. The Medicines Company (MDCO) Rating Reiterated by Jefferies GroupRead the original story w/Photo

    Wednesday Jun 15 | AmericanBankingNews.com

    ... have modified their holdings of the company. BlackRock Inc. increased its position in shares of The Medicines Company by 28.3% in the first quarter. BlackRock Inc. now owns 4,554 shares of the company's stock valued at $145,000 after buying an ...

    Comment?

  11. The Medicines Company initiates phase II study of ABP-700Read the original story w/Photo

    Tuesday Jun 14 | Seeking Alpha

    The Medicines Company announces that it has dosed the first patient in a Phase II study of ABP-700, an investigational product developed for the induction of general anesthesia and procedural sedation. The mid-stage study follows within weeks of completion of Phase I clinical pharmacology, dosing and safety studies.

    Comment?

  12. The Medicines Company Announces Initiation Of Phase II Study For Its...Read the original story

    Monday Jun 13 | BioSpace

    The Medicines Company announced today that it has dosed the first patient in a Phase II study of ABP-700 in procedural sedation. The Phase II study follows within weeks of completion of Phase I clinical pharmacology, dosing and safety studies, including its use with pre- and co-medications routinely given as part of procedural sedation and induction of general anesthesia.

    Comment?

  13. The Medicines Company (MDCO) EVP Christopher T. Cox Purchases 45,985 SharesRead the original story w/Photo

    Monday Jun 13 | Daily Political

    The Medicines Company EVP Christopher T. Cox acquired 45,985 shares of the stock in a transaction on Friday, June 10th. The stock was bought at an average price of $37.90 per share, with a total value of $1,742,831.50.

    Comment?

  14. SymBio Pharma Release: Initiation Of Phase III Clinical Trial On The...Read the original story

    Sunday Jun 12 | BioSpace

    SymBio Pharmaceuticals Limited announced today that the Phase 3 clinical trial on "SyB P-1501" - a drug for patient-controlled short-term management of acute postoperative pain during hospitalization, was initiated in Japan, . SymBio obtained the exclusive development and commercialization rights to the Product in Japan from The Medicines Company in October, 2015.

    Comment?

  15. The Medicines Company Announces Participation At To Be Held June 16 ??? 20 In BostonRead the original story

    Sunday Jun 12 | BioSpace

    Total of 11 presentations highlighting company's infectious disease program targeted at the most urgent needs in combating resistant organisms PARSIPPANY, N.J.-- -- The Medicines Company today announced that 11 presentations on its infectious disease programs will be presented at the first annual ASM Microbe 2016 to be held June 16-20 in Boston, MA. The company's infectious disease R&D program is targeted at the most deadly and insidious bacterial threats threatening global health.

    Comment?

  16. Initiation of Phase 3 Clinical Trial on the Patient-controlled Pain Management Drug "SyB P-1501"Read the original story

    Sunday Jun 12 | GlobeNewswire

    SymBio Pharmaceuticals Limited announced today that the Phase 3 clinical trial on "SyB P-1501" - a drug for patient-controlled short-term management of acute postoperative pain during hospitalization, was initiated in Japan, . SymBio obtained the exclusive development and commercialization rights to the Product in Japan from The Medicines Company in October, 2015.

    Comment?

  17. The Medicines Company (MDCO) EVP Christopher T. Cox Buys 45,985 SharesRead the original story w/Photo

    Friday Jun 10 | AmericanBankingNews.com

    The Medicines Company EVP Christopher T. Cox acquired 45,985 shares of the stock in a transaction that occurred on Friday, June 10th. The stock was acquired at an average price of $37.90 per share, with a total value of $1,742,831.50.

    Comment?

  18. The Medicines Company (MDCO) EVP Purchases $2,002,917.00 in StockRead the original story w/Photo

    Wednesday Jun 8 | AmericanBankingNews.com

    The Medicines Company EVP Christopher T. Cox purchased 53,340 shares of The Medicines Company stock in a transaction that occurred on Tuesday, June 7th. The stock was acquired at an average cost of $37.55 per share, with a total value of $2,002,917.00.

    Comment?

  19. Why Investors Have This Drug Makersa Stocks on Their Radar? a " Carbylan Therapeutics,...Read the original story

    Monday Jun 6 | Freshnews

    The Generic Drugs space is an attractive yet very competitive industry. In today's lineup, ActiveWallSt.com have these companies: Carbylan Therapeutics Inc. , Catalent Inc. , The Medicines Co.

    Comment?

  20. The Medicines Company to offer $350M in convertible debtRead the original story w/Photo

    Monday Jun 6 | Seeking Alpha

    The Medicines Company announces its intention to offer $350M aggregate principal amount of convertible senior notes due 2023. The notes will be convertible, subject to conditions, into cash, shares of the company's common stock or a combination of the two, at MDCO's option.

    Comment?